Condition: Penile Squamous Cell Carcinoma (PSCC) · Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
The DEPECA-1 trial is the first systematic Phase II trial to evaluate response and survival to a combination of antibody-drug conjugate enfortumab vedotin plus the PD-L1 inhibitor avelumab in patients with locally advanced and metastatic penile squamous cell carcinoma (PeCa) in the 1st line setting.
This description comes directly from the study's public registry record.
Igor Tsaur, Prof. Dr. · +49 7071-29-86000 · igor.tsaur@med.uni-tuebingen.de
Claudia Pauligk, Dr. · +49 69 5899 787 52 · depeca-1@ikf-khnw.de
Always discuss trial participation with your own doctor first.
| Universitätsklinikum Carl Gustav Carus | Dresden, Germany | Recruiting |
| University Hospital and Medical Faculty, Heinrich-Heine-University, Düsseldorf | Düsseldorf, Germany | Recruiting |
| University Medical Center of Johannes Gutenberg-University | Mainz, Germany | Recruiting |
| University Hospital Mannheim | Mannheim, Germany | Recruiting |
| Technical University of Munich, University Hospital Munich | Munich, Germany | Recruiting |
| Caritas St. Josef Medical Center | Regensburg, Germany | Recruiting |
| Rostock University Medical Center | Rostock, Germany | Recruiting |
| University Hospital Tübingen | Tübingen, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07110038